Boston, Massachusetts
CNS medication trials in Boston, MA
58 CNS medication studies are recruiting participants at sites in Boston as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Boston at a glance
- 58 studies are recruiting at a site in Boston.
- By phase: Early Phase 1 (1), Phase 1 (4), Phase 1/2 (3), Phase 2 (12), Phase 2/3 (1), Phase 3 (26), Phase 4 (11).
- By sponsor: industry (37), university, hospital or other (19), government (2).
- By research area: Depression (20), Multiple Sclerosis (11), Parkinson's Disease (10), Schizophrenia (8), ADHD (5), Epilepsy (2), Migraine (2).
- Most recent update to one of these records: November 17, 2026.
Depression studies recruiting in Boston
Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study site
- Adams Clinical Boston
- Registry record
- NCT06793397 · updated
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Massachusetts General Hospital
- Study site
- Massachusetts General Hospital
- Registry record
- NCT05450432 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- Dana Farber Cancer Institute
- Registry record
- NCT07002034 · updated
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Seaport Therapeutics
- Study site
- Seaport Investigator Site
- Registry record
- NCT07065240 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Adams Clinical Watertown
- Registry record
- NCT07592689 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Adams Clinical Boston
- Registry record
- NCT07412756 · updated
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Boston Childrens Hospital
- Registry record
- NCT07227454 · updated
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Adams Clinical Boston
- Registry record
- NCT07573176 · updated
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Adams Clinical Boston
- Registry record
- NCT07775300 · updated
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Neurocrine Biosciences
- Study site
- Neurocrine Clinical Site
- Registry record
- NCT06966401 · updated
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
- Phase 2
- Ages 25 to 50
- All sexes
- Sponsor
- Massachusetts General Hospital
- Study site
- Massachusetts General Hospital
- Registry record
- NCT06136546 · updated
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Elizabeth Austen Lawson
- Study site
- Massachusetts General Hospital, Neuroendocrine Unit
- Registry record
- NCT04789148 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Boston, MA on ClinicalTrials.gov.
Schizophrenia studies recruiting in Boston
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Phase 3
- Ages 13 to 17
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Boston Children's Hospital
- Registry record
- NCT07288567 · updated
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Boston Children's Hospital
- Registry record
- NCT07424404 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Tufts Medical Center - 800 Washington St - PPDS
- Registry record
- NCT06585787 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Boston, MA on ClinicalTrials.gov.
ADHD studies recruiting in Boston
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study site
- Boston Clinical Trials
- Registry record
- NCT07759154 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Boston, MA on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Boston
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Dana Farber Cancer Hospital ( Site 0155) · Massachusetts General Hospital ( Site 0136)
- Registry record
- NCT06623422 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Tufts Medical Center ( Site 6052)
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Dana Farber Cancer Institute ( Site 0090) · Massachusetts General Hospital Cancer Center ( Site 0091)
- Registry record
- NCT06966700 · updated
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
- Phase 2
- Ages 50 to 80
- All sexes
- Sponsor
- Yale University
- Study site
- Massachusetts General Hospital
- Registry record
- NCT06996652 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Beth Israel Deaconess Medical Center
- Registry record
- NCT06680830 · updated
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- Phase 2
- Ages 30 to 80
- All sexes
- Sponsor
- Appello Pharmaceuticals, Inc.
- Study site
- Beth Israel Deaconess Medical Center (Site #211)
- Registry record
- NCT07432958 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Boston, MA on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Dana-Farber Cancer Institute · Massachusetts General Hospital Cancer Center
- Registry record
- NCT03816345 · updated
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
- Phase 3
- Ages 25 to 75
- All sexes
- Sponsor
- MGH Institute of Health Professions
- Study site
- MGH Institute of Health Professions
- Registry record
- NCT06136728 · updated
Efgartigimod for the Treatment of Acute Optic Neuritis
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
- Study sites
- Massachusetts Eye and Ear Infirmary · Massachusetts General Hospital
- Registry record
- NCT06453694 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Boston, MA on ClinicalTrials.gov.
Epilepsy studies recruiting in Boston
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- Phase 4
- Ages 18 and older
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
- Registry record
- NCT04419272 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Boston, MA on ClinicalTrials.gov.
Migraine studies recruiting in Boston
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Boston Clinical Trials - Alcanza
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Boston Clinical Trials - Alcanza
- Registry record
- NCT07674654 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Boston, MA on ClinicalTrials.gov.
Ask about studies near Boston
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections